Physicochemical Characterization of Nanomedicines

Dark-Field optical microscope with spectral analysis

Scientific Leaders of the project: Jaume Veciana, Nora Ventosa, Jesús Santamaría, José Luis Pedraz & Carlos Rodríguez.

Coordinator of the project: Jaume Veciana

Industrial problem/gap covered

One of the causes that increase the time to market of nanotherapeuticsis its preclinical validation. The standard protocols for more traditional drugs are not applicable for nanomedicines. NANBIOSISoffers a preclinical study plan tailored to meet the demands of each nanomedicine product, developed in collaboration with the user and starting from a set of basic analytical tests to more sophisticated experiments. Also, some of them are available under GLP for regulatory pruposes.

Description

We offer a complete Physicochemical Characterization. e.g., size distribution, composition, purity, surface characteristics, stability, and more adapted to the different products by using the most sophisticated equipment and taking advantage of the expertise of scientist internationally recognized in the matter.

Services involved: Standar services

• Size of Nanoparticles (NP)by:
  • AtomicForceMicroscopy (U6, U9, U10 & U12)
  • TransmissionElectronMicroscopy (U6 & U9)
  • Electrospray Differential Mobility Analysis (U6 & U9)
  • High-Resolution Scanning Electron Microscopy (U6 & U9)
  • DLS y MALS (Size, Size Distribution)(U12)
  • X-ray diffraction (solid NP) (U10)
• Measuring NP aggregation propensities with DLS (U6, U9& U12)
• Zeta Potential (U6, U9, U10 & U12)
• pH of NP Suspensions (U6, U9, U10 & U12)
• Lipid composition (U6 & U12)
• Determination of Metallic NPs in Blood or in Rat Tissue with Inductively Coupled Plasma-Mass Spectrometry(ICP-MS) (U9)
• Quantification of Free and Chelated Gadolinium Species in Nanoemulsion-Based MRI Contrast Agent Formulations using Hyphenated Chromatography Methods (U6)
• LC/MS/MS y Free vs. encapsulated drug under either GLP (U10) or non-GLP (U6, U9 & U12)
• Stability of the active or the final pharmaceutical form (according to ICH) under either GLP or non-GLP (U10)
• Solubility profiles of the final pharmaceutical formunder either GLP or non-GLP (U10)

 

Others

• Concentration, charge & Size of Flourescent NP by NanotrackingParticle Analysis (U6)
• Optical Analysis by Nano-scale Optical Microscope: Dark-Field optical microscope with spectral analysis (U12)
• Size of particles in formulations for pulmonary delivery (aerosols and nebulized) (U10)
• Determination of aerodynamic size (U10)
• Surface Functional groups by ATR (U6&U9)
• Surface Organic material in metallic NP by TGA (U9)
• Accessible surface charge of NP and size pore (BET) (U9)
• Composition by XPS (U9)
• Biomolecule-NP interaction by ITC (U6)
• Density of solids by pycnometer (U6)
• Size & morphology of concentrated systems by 3D DLS & SLS multiangle (MALS)
• Rheology (viscosity, shear-thinning, shear thickening, elastic and viscous modulus, relaxation times,etc) (U12)
• Refraction index and density of liquids (U12)
• Critical micellar concentration, surface and interfacial tension of pure liquids, solutions and colloidal dispersion (U12)
• Structural determination by SAXS (U12)

 

Some examples are described in the following publications:

Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis, M. Moreno-Sastre, M. Pastor, A. Esquisabel, E. Sans, M. Viñas, A. Fleischer, E. Palomino, D. Bachiller, J. L. Pedraz. International Journal of Pharmaceutics 498 (2016) 263–273.

Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic Fibrosis. M. Moreno-Sastre, M. Pastor, A. Esquisabel, E. Sans, M. Viñas, A, D. Bachiller, V.J. Asensio, Á. Del Pozo, E. Gainza and J. L. Pedraz. International Journal of Pharmaceutics 477 (2014) 485–494

α-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. I. Cabrera, I. Abasolo, J. L. Corchero, E. Elizondo, P. Rivera Gil, E. Moreno, J. Faraudo, S. Sala, D. Bueno, E. González-Mira, M. Rivas, M. Melgarejo, D.Pulido, F. Albericio, M. Royo, A.Villaverde, M.F. García-Parajo, S. Schwartz Jr., N. Ventosa,* and Jaume Veciana* Adv. Healthcare Mater. 2016, DOI: 10.1002/adhm.201500746

Multifunctional Nanovesicle-Bioactive Conjugates Prepared by a One-Step Scalable Method Using CO2-Expanded Solvents. I. Cabrera, E. Elizondo, O. Esteban, J. L. Corchero, M. Melgarejo, D. Pulido, A. Córdoba, E. Moreno, U. Unzueta, E. Vazquez, I. Abasolo, S. Schwartz, Jr., A. Villaverde, F. Albericio, M. Royo, M. F. García-Parajo, N. Ventosa, and J. Veciana. Nano Letters 2013 13 (8), 3766-3774. DOI: 10.1021/nl4017072